Clinical trial
Fluselenamyl - Beta Amyloid PET Imaging for Alzheimer Disease
NCT05731440 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Fluselenamyl - Beta Amyloid PET Imaging for Alzheimer Disease
- Lead sponsor
- Washington University School of Medicine
- Phase
- Observational
- Overall status
- Active, not recruiting
- Start date
- November 18, 2022
- Completion date
- December 31, 2027
- Enrollment
- 60 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.